Bristol-Myers Squibb stock holds steady as CAR-T trial pause meets solid dividend and pipeline outlook
Published on 09/03/2026 at 21:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock (ISIN US1078421011) is trading at about 67.53 USD on the New York Stock Exchange as of September 3, 2026, according to recent market data, keeping the shares in the mid-60 USD range after a year-to-date climb from around 53.93 USD at the beginning of 2026.
CAR-T trial pause shapes near-term sentiment
A key catalyst for Bristol-Myers Squibb in early September 2026 is the company’s decision, alongside another large pharma peer, to pause several clinical trials evaluating CAR-T cell therapies for autoimmune conditions after inflammatory side effects were observed in testing, as reported by Ground News.
According to a detailed industry update from Pharmaceutical Executive dated September 2, 2026, Bristol-Myers Squibb has halted enrollment in its Zola-cel autoimmune trials, including a planned systemic sclerosis study, after routine monitoring detected transient, reversible inflammatory events, and the company states that it is reviewing the data with an aim to resume as quickly as possible.
Dividend yield and YTD performance underpin the share price
Market data compiled by MarketBeat on September 3, 2026 show Bristol-Myers Squibb stock at 67.53 USD as of mid-morning Eastern time, with the shares up approximately 25.3 percent year to date from a start level of 53.93 USD at the beginning of 2026, illustrating a clear recovery phase in the valuation.
The same MarketBeat data indicate a previous close close to the current price level, pointing to limited immediate price reaction to the CAR-T pause and suggesting that investors are balancing the trial uncertainty against the company’s broader pipeline and income profile.
More on Bristol-Myers Squibb stock and reports
For additional price data, news headlines and upcoming corporate reporting dates on Bristol-Myers Squibb, the dedicated topic page provides a compact overview of recent developments.
Pipeline highlights: Camzyos and oncology portfolio
Beyond the CAR-T pause, Bristol-Myers Squibb continues to work on a range of late-stage assets and marketed therapies, including the heart failure therapy Camzyos and oncology candidates such as gridegalutamide, which is being evaluated in a phase 3 study in metastatic castration-resistant prostate cancer according to a research overview in Nature Medicine dated September 3, 2026.
Industry commentary on September 3, 2026 cited by MarketBeat also notes that recent data for Camzyos have supported the stock in earlier sessions, with discussions focusing on whether the upside from this therapy is already reflected in the current share price.
Representative product: Camzyos in focus for growth
Camzyos, a therapy for obstructive hypertrophic cardiomyopathy, has become one of Bristol-Myers Squibb’s key growth drivers, with investor discussions frequently highlighting the potential revenue contribution over the next few years as the product expands its label and geographic reach.
Stock price and trading context
As of September 3, 2026, Bristol-Myers Squibb stock is quoted at 67.53 USD on the New York Stock Exchange, placing the shares above their early-2026 level of 53.93 USD and reflecting a year-to-date performance of 25.3 percent according to MarketBeat data, within a broader Wall Street environment where large pharmaceutical names remain supported by defensive demand.
Key data on Bristol-Myers Squibb stock
- Company: Bristol-Myers Squibb Company
- ISIN: US1078421011
- Ticker: BMY
- Trading venue: New York Stock Exchange
- Price (as of September 3, 2026, 11:03): 67.53 USD
- Market capitalization: 136.7 billion USD (as of September 2, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
